Evkeeza (Evinacumab-dgnb)

Evkeeza (Evinacumab-dgnb)

Evkeeza

Evinacumab-dgnb

Injection: 345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) solution in single-dose vials

Regeneron Pharmaceuticals, Inc

Medical Use

Evkeeza is an injectable medication that inhibits ANGPTL3 (angiopoietin-like 3). It is used alongside other LDL-C (low-density lipoprotein cholesterol) lowering treatments to manage homozygous familial hypercholesterolemia (HoFH) in adults and children aged 12 and older.

Dosage Instructions:

The recommended dosage is 15 mg/kg, administered via intravenous (IV) infusion every 4 weeks. Ensure that Evkeeza is not mixed with other medications or administered simultaneously through the same infusion line.

Administration Notes :

If a patient experiences side effects such as hypersensitivity reactions, the infusion rate may need to be adjusted, paused, or stopped.

Missed Dose :

If a dose is missed, it should be administered as soon as possible. To maintain effectiveness, schedule the medication monthly from the last dose.